Advances in Cancer Immunotherapy in Solid Tumors

We examine recent advances in the understanding of Tumor Immunity, some of the key therapeutic innovations and the unique side effects and clinical caveats while using Immunotherapy

Smitha Menon


Scholarcy highlights

  • Our body’s immune system maintains a very sophisticated and powerful defense against “non self” antigens
  • Ipilimumab is approved for adjuvant treatment of high risk melanoma based on the results of a European Organization for Research and Treatment of Cancer 18071 trial which showed improved relapse free survival compared to placebo, with three-year RFS of 46.5% vs. 34.8%, hazard ratio
  • A Phase II trial characterizing the role of anti-PD1 immunotherapy in patients with colorectal cancers with high microsatellite instability found that patients with colorectal cancers that have deficient mismatch repair mechanism had significantly improved responses and immune-related progression-free survival rates than those who had cancers with an intact mismatch repair
  • Preclinical studies with adoptive cell transfer of T cells expressing chimeric antigen receptors against mesothelin, a tumor antigen associated with decreased survival and overexpressed on the surfaces of more than 90% of epithelioid malignant pleural mesothelioma, resulted in enhanced T cell recruitment towards MSLN+ cells and a 2- to 5-fold increase in Th1 cytokine secretion
  • It is evident that there is tremendous growth in the field of Immune Oncology stemming from improved understanding of the interaction among cancer cells, Tumor Microenvironment and the body’s immune system
  • The ultimate objective would be getting closer to the Holy Grail in cancer that is the development of curative therapy even in metastatic disease

Need more features? Save interactive summary cards to your Scholarcy Library.